Tags

Type your tag names separated by a space and hit enter

Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Dement Geriatr Cogn Disord. 2004; 17(1-2):5-13.DG

Abstract

In the present study, the socioeconomic impact of the use of the acetylcholinesterase inhibitor donepezil in patients with mild to moderate Alzheimer's disease (AD) living in France was examined. A model was created to extrapolate over a 3-year period the results from placebo-controlled trials together with epidemiological and prevalence data. Costs considered in the model were net societal costs associated with paid and unpaid assistance, general medical consumption and institutional care. The model suggested that delays in cognitive decline and functional dependence due to treatment reduced the time spent in institutional care and the burden on caregivers. Over a 3-year period, total net costs of caring for untreated patients with an initial Mini-Mental State Examination score ranging from 10 to 26 were EUR 53,206 compared with EUR 42,720 for a patient treated with donepezil--an annual cost saving of approximately EUR 3,500 per patient. Cost savings were mainly due to savings in unpaid caregiver time, which, apart from patient institutionalization, represented the most costly component of total care in this study but had no direct budgetary impact. Overall, these data suggest that donepezil is a cost-effective treatment for mild to moderately impaired AD patients living in France.

Authors+Show Affiliations

CEMKA, Bourg-la-Reine, France. francis.fagnani@cemka.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14560059

Citation

Fagnani, F, et al. "Donepezil for the Treatment of Mild to Moderate Alzheimer's Disease in France: the Economic Implications." Dementia and Geriatric Cognitive Disorders, vol. 17, no. 1-2, 2004, pp. 5-13.
Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord. 2004;17(1-2):5-13.
Fagnani, F., Lafuma, A., Pechevis, M., Rigaud, A. S., Traykov, L., Seux, M. L., & Forette, F. (2004). Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dementia and Geriatric Cognitive Disorders, 17(1-2), 5-13.
Fagnani F, et al. Donepezil for the Treatment of Mild to Moderate Alzheimer's Disease in France: the Economic Implications. Dement Geriatr Cogn Disord. 2004;17(1-2):5-13. PubMed PMID: 14560059.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. AU - Fagnani,F, AU - Lafuma,A, AU - Pechevis,M, AU - Rigaud,A S, AU - Traykov,L, AU - Seux,M L, AU - Forette,F, Y1 - 2003/10/13/ PY - 2003/05/27/accepted PY - 2003/10/16/pubmed PY - 2004/2/28/medline PY - 2003/10/16/entrez SP - 5 EP - 13 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 17 IS - 1-2 N2 - In the present study, the socioeconomic impact of the use of the acetylcholinesterase inhibitor donepezil in patients with mild to moderate Alzheimer's disease (AD) living in France was examined. A model was created to extrapolate over a 3-year period the results from placebo-controlled trials together with epidemiological and prevalence data. Costs considered in the model were net societal costs associated with paid and unpaid assistance, general medical consumption and institutional care. The model suggested that delays in cognitive decline and functional dependence due to treatment reduced the time spent in institutional care and the burden on caregivers. Over a 3-year period, total net costs of caring for untreated patients with an initial Mini-Mental State Examination score ranging from 10 to 26 were EUR 53,206 compared with EUR 42,720 for a patient treated with donepezil--an annual cost saving of approximately EUR 3,500 per patient. Cost savings were mainly due to savings in unpaid caregiver time, which, apart from patient institutionalization, represented the most costly component of total care in this study but had no direct budgetary impact. Overall, these data suggest that donepezil is a cost-effective treatment for mild to moderately impaired AD patients living in France. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/14560059/Donepezil_for_the_treatment_of_mild_to_moderate_Alzheimer's_disease_in_France:_the_economic_implications_ L2 - https://www.karger.com?DOI=10.1159/000074079 DB - PRIME DP - Unbound Medicine ER -